Loading patent…
AssigneeGlaxosmithkline Biologicals SA
InventorsNathalie Garcon, Moncef Mohamed Slaoui, Christian Van Hoecke
Estimating the term…
The invention relates to the use of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation, in the manufacture of a one-dose influenza vaccine for intradermal delivery. In particular, the invention relates to the use of split influenza preparations wherein the vaccine comprises at least one non-ionic surfactant selected from the group consisting of the octyl-or nonylphenoxy polyoxyethanols (for example the commercially available Triton™ series), polyoxyethylene sorbitan esters (Tween™ series) and polyoxyethylene ethers or esters of general formula (I): HO(CH2CH2O)n-A-R, wherein n is 1-50, A is a bond or —C(O)—, R is C1-50 alkyl or phenyl C1-50 alkyl; and combinations of two or more of these.
A method for inducing a protective immune response in a human population of at least 18 years old comprising administering intradermally a single dose of a trivalent, split or subunit influenza vaccine antigen preparation using a short needle device, wherein the single dose results in said protective immune response meeting at least one criterion chosen from the group of:
A method for inducing a protective immune response in a human population of at least 18 years old comprising administering intradermally a single dose of a trivalent, split or subunit influenza vaccine antigen preparation using a short needle device, wherein said protective immune response meets at least two criteria chosen from the group of:
A method for inducing a protective immune response in a human population of at least 18 years old comprising administering intradermally a single dose of a trivalent, split or subunit influenza vaccine antigen preparation using a short needle device, wherein said protective immune response meets all criteria chosen from the group:
Dependencies are inferred from the claim text.